156 related articles for article (PubMed ID: 34125179)
21. High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors.
Wolkow N; Jakobiec FA; Afrogheh AH; Pai SI; Faquin WC
Am J Ophthalmol; 2020 Dec; 220():128-139. PubMed ID: 32730911
[TBL] [Abstract][Full Text] [Related]
22. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.
Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR
Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385
[TBL] [Abstract][Full Text] [Related]
23. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
24. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment.
Umezu D; Okada N; Sakoda Y; Adachi K; Ojima T; Yamaue H; Eto M; Tamada K
Cancer Immunol Immunother; 2019 Feb; 68(2):201-211. PubMed ID: 30357491
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
[TBL] [Abstract][Full Text] [Related]
27. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
[TBL] [Abstract][Full Text] [Related]
28. PD-L1
Pollari M; Brück O; Pellinen T; Vähämurto P; Karjalainen-Lindsberg ML; Mannisto S; Kallioniemi O; Kellokumpu-Lehtinen PL; Mustjoki S; Leivonen SK; Leppä S
Haematologica; 2018 Nov; 103(11):1908-1914. PubMed ID: 30026337
[TBL] [Abstract][Full Text] [Related]
29. The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection.
Zhang E; Zhang X; Liu J; Wang B; Tian Y; Kosinska AD; Ma Z; Xu Y; Dittmer U; Roggendorf M; Yang D; Lu M
PLoS One; 2011; 6(10):e26196. PubMed ID: 22022563
[TBL] [Abstract][Full Text] [Related]
30. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Lesokhin AM; Ansell SM; Armand P; Scott EC; Halwani A; Gutierrez M; Millenson MM; Cohen AD; Schuster SJ; Lebovic D; Dhodapkar M; Avigan D; Chapuy B; Ligon AH; Freeman GJ; Rodig SJ; Cattry D; Zhu L; Grosso JF; Bradley Garelik MB; Shipp MA; Borrello I; Timmerman J
J Clin Oncol; 2016 Aug; 34(23):2698-704. PubMed ID: 27269947
[TBL] [Abstract][Full Text] [Related]
31. GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors.
Fu Y; Liu CJ; Kobayashi DK; Johanns TM; Bowman-Kirigin JA; Schaettler MO; Mao DD; Bender D; Kelley DG; Uppaluri R; Bi WL; Dunn IF; Tao Y; Luo J; Kim AH; Dunn GP
Sci Rep; 2020 Jun; 10(1):9027. PubMed ID: 32493985
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules.
Zhang Y; Chen X; Mo S; Ma H; Lu Z; Yu S; Chen J
J Pathol Clin Res; 2022 May; 8(3):257-267. PubMed ID: 35037417
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
[TBL] [Abstract][Full Text] [Related]
34. Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.
Liu J; Li H; Sun L; Yuan Y; Xing C
Biomed Res Int; 2020; 2020():2496582. PubMed ID: 32596285
[TBL] [Abstract][Full Text] [Related]
35. Targetable genetic features of primary testicular and primary central nervous system lymphomas.
Chapuy B; Roemer MG; Stewart C; Tan Y; Abo RP; Zhang L; Dunford AJ; Meredith DM; Thorner AR; Jordanova ES; Liu G; Feuerhake F; Ducar MD; Illerhaus G; Gusenleitner D; Linden EA; Sun HH; Homer H; Aono M; Pinkus GS; Ligon AH; Ligon KL; Ferry JA; Freeman GJ; van Hummelen P; Golub TR; Getz G; Rodig SJ; de Jong D; Monti S; Shipp MA
Blood; 2016 Feb; 127(7):869-81. PubMed ID: 26702065
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy for Esophageal and Gastric Cancer.
Kelly RJ
Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 Expression in Mastocytosis.
Williams M; Lidke DS; Hartmann K; George TI
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31086024
[TBL] [Abstract][Full Text] [Related]
38. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis.
Riemersma SA; Oudejans JJ; Vonk MJ; Dreef EJ; Prins FA; Jansen PM; Vermeer MH; Blok P; Kibbelaar RE; Muris JJ; Schuuring EM; Kluin PM
J Pathol; 2005 Jul; 206(3):328-36. PubMed ID: 15887291
[TBL] [Abstract][Full Text] [Related]
39. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
[TBL] [Abstract][Full Text] [Related]
40. High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.
Ludovini V; Bianconi F; Siggillino A; Vannucci J; Baglivo S; Berti V; Tofanetti FR; Reda MS; Bellezza G; Mandarano M; Belladonna ML; Metro G; Chiari R; Sidoni A; Puma F; Minotti V; Roila F
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33671892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
